Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications by Dimitrios Balafoutas et al.
Balafoutas et al. BMC Cancer 2013, 13:271
http://www.biomedcentral.com/1471-2407/13/271RESEARCH ARTICLE Open AccessCancer testis antigens and NY-BR-1 expression in
primary breast cancer: prognostic and therapeutic
implications
Dimitrios Balafoutas1, Axel zur Hausen2, Sebastian Mayer1, Marc Hirschfeld1,3,4, Markus Jaeger1,
Dominik Denschlag1, Gerald Gitsch1, Achim Jungbluth5 and Elmar Stickeler1*Abstract
Background: Cancer–testis antigens (CTA) comprise a family of proteins, which are physiologically expressed in
adult human tissues solely in testicular germ cells and occasionally placenta. However, CTA expression has been
reported in various malignancies. CTAs have been identified by their ability to elicit autologous cellular and or
serological immune responses, and are considered potential targets for cancer immunotherapy. The breast
differentiation antigen NY-BR-1, expressed specifically in normal and malignant breast tissue, has also immunogenic
properties. Here we evaluated the expression patterns of CTAs and NY-BR-1 in breast cancer in correlation to
clinico-pathological parameters in order to determine their possible impact as prognostic factors.
Methods: The reactivity pattern of various mAbs (6C1, MA454, M3H67, 57B, E978, GAGE #26 and NY-BR-1 #5) were
assessed by immunohistochemistry in a tissue micro array series of 210 randomly selected primary invasive breast
cancers in order to study the diversity of different CTAs (e.g. MAGE-A, NY-ESO-1, GAGE) and NY-BR-1. These
expression data were correlated to clinico-pathological parameters and outcome data including disease-free and
overall survival.
Results: Expression of at least one CTA was detectable in the cytoplasm of tumor cells in 37.2% of the cases. NY-BR-1
expression was found in 46.6% of tumors, respectively. Overall, CTA expression seemed to be linked to adverse
prognosis and M3H67 immunoreactivity specifically was significantly correlated to shorter overall and disease-free
survival (p=0.000 and 0.024, respectively).
Conclusions: Our findings suggest that M3H67 immunoreactivity could serve as potential prognostic marker in primary
breast cancer patients. The exclusive expression of CTAs in tumor tissues as well as the frequent expression of NY-BR-1
could define new targets for specific breast cancer therapies.
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Breast cancer is the second most common human ma-
lignancy [1]. In recent years the progress in systemic
treatment modalities, especially endocrinological, immuno-
and chemotherapeutical strategies, have substantially re-
duced the proportion of women who develop metastatic
disease. In the context of these advances the importance to
identify prognostic and predictive markers is steadily* Correspondence: elmar.stickeler@uniklinik-freiburg.de
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reproduction in any medium, provided the orincreasing in order to avoid unnecessary adjuvant therapy
regimens [2].
Cancer testis antigens (CTAs) comprise an expanding
family of proteins which are normally expressed in
human testicular germ cells or placental trophoblast, but
not in any other normal tissue. However, CTAs are
present in various malignancies [3]. More than 100
CTA-related genes and/or gene families have been iden-
tified, however their biological function remains poorly
understood. CTA encoding genes which are located on
chromosome X are referred to as CT-X antigens.
Expression of these antigens has been found in diversetral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Because of their restricted expression, CTAs are consid-
ered relevant to cancer biology and their prognostic
relevance has been assessed in the recent years by
several studies for various malignancies [5,6]. Yet the
prognostic significance of CTAs in breast cancer still
remains unclear.
Interestingly the presence of some CTAs such as,
MAGE-A family members, GAGE and NY-ESO-1 ap-
pears to correlate with clinico-pathological parameters
and prognosis in tumors, such as melanoma, non-small-
cell lung cancer, multiple myeloma and other tumors
[7]. CTAs are frequently recognized by cytotoxic T-
lymphocytes of cancer patients or they can elicit a
serological immune response in the autologous host [8].
Consequently, CTAs are regarded potential candidates
for the development of anti-cancer vaccines [9,10]. Spe-
cifically NY-ESO-1 is able to elicit combined humoral
and cell mediated immune response and considered to
be the most immunogenic of the above antigens. There-
fore NY-ESO-1 based vaccines have been employed in
several clinical vaccination trials [11].
NY-BR-1 is a differentiation antigen of the mammary
tissue, since it has been detected solely in the epithelial
cells of mammary ducts and lobules, whereas NY-BR-1
expression has not been found in any other tissue [12].
Thus, NY-BR-1 appears to be a breast-specific protein.
At present only few reports on CTA expression patterns
and their prognostic role in breast cancer are available
with limited number of patients and clinical correlations
and in part controversial findings [4,13-18]. The objective
of this study was to examine the expression pattern of the
aforementioned CT-antigens as well as NY-BR-1 in breast
cancer and to correlate them with clinico-pathological
parameters including patient outcome data. This study is
the first to analyze simultaneously the expression of the




For this study 210 consecutive patients diagnosed with
invasive breast cancer were enrolled, according to the
ethics committee of the University Hospital Freiburg,
Germany (EK-Freiburg 324/09). Standard archival paraffin
blocks of primary breast cancer were retrieved from the
archives of the Department of Pathology of the University
Hospital Freiburg. All patients underwent surgery in the
Breast Unit of the Department of Gynecology of the
University Hospital Freiburg. Primary treatment consisted
of radical mastectomy, modified radical mastectomy, or
breast-conserving surgery including sentinel and/or axil-
lary lymph node dissection between the years 1991 and
2001. Patients who received neoadjuvant chemotherapy,or who underwent preceding treatment at another insti-
tution or patients with a second primary tumor were ex-
cluded. Median age at the time of diagnosis was
57 years. Histopathological analyses demonstrated inva-
sive ductal cancer in 73.8% of cases and invasive lobular
subtype in 7.6%. The remaining 18.6% were diagnosed
as ductal/lobular, mucinous (colloid), tubular, medullary
and papillary carcinomas, respectively. In 88/210 (41.9%)
patients lymph node involvement was histologically
confirmed at the time of surgery. 146/210 (69.5%) of the
tumors were estrogen or progesterone receptor positive.
Immunohistochemical Her2/neu overexpression was
recorded in 40 (21.2%) of the cases.
Follow up ranged from 1 to 107 months (mean 62,
median 68 months), recurrences occurred in 59 (28.1%)
and deaths in 43 (20.5%) of women, respectively. The 63
cases with technical failure in microarray mapping were
excluded from the study.
Materials
Paraffin-embedded tissue blocks were used to generate
tissue-microarrays (TMAs). At least three representative
cores of each tumor were selected. Two specimens of
normal breast as well as non neoplastic breast tissue ad-
jacent to the lesions were used as controls. Four micron
paraffin sections were stained immunohistochemically as
previously described [16]. The following monoclonal
antibodies (mAbs) were used: mAb 6C1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, USA) to several members
of the MAGE-A family, mAb MA454 to MAGE-A1, mAb
M3H67 also to several members of the MAGE-A family
and mAb 57B to MAGE-A4 [19-21]. Next to these, the
immunoreactivity of mAb E978 to NY-ESO-1 [22] and
mAb #26 (BD Biosciences Clontech, Palo Alto, USA) to
GAGE was assessed. For the detection of NY-BR-1, mAb
NY-BR-1#5 previously generated by our group was
utilized [23].
Evaluation of the immunohistochemical staining was
performed in a blinded set up regarding the clinical data.
Scoring of the expression was performed semiquantita-
tively as described previously [24]. In brief, both percent-
age of stained cells and staining intensity were evaluated.
No staining or weak staining in <5% of cells was defined
as 0, weak staining in at least 5% as 1, moderate staining
in up to 50% as 2 and moderate staining in >50% of cells
and strong staining of any percentage of the cells as 3.
The results were subsequently dichotomized for statis-
tical analysis and the defined cut-off point for positivity
for the statistical analysis was set to 2.
Our data were analysed using the statistical package
SPSS for windows version 17.0 (SPSS, Chicago, Illinois,
USA). The relationship among clinico-pathological
parameters and CTA expression were tested using the
chi-square and Fisher’s exact test. Survival outcomes
Balafoutas et al. BMC Cancer 2013, 13:271 Page 3 of 10
http://www.biomedcentral.com/1471-2407/13/271were analysed with Kaplan-Meier survival functions and
compared between groups with the log-rank statistics.
To determine the association of clinico-pathological
parameters with survival, univariate and multivariate
Cox regression models were used. The multivariate Cox
regression model was adjusted for any known prognostic
variables with p<0.05. For all tests p<0.05 was accepted as
threshold of statistical significance. Cases with missing
microarrays for some of the antigens were handled in the
statistical analysis as missing data.Results
Expression of CTAs and NY-BR1 in invasive breast cancer
Overall, CTA expression was restricted to neoplastic
breast tissues and detected in 54 tumor samples (37.2%)
(Table 1). The expression was mainly restricted to the
cytoplasm and only occasionally located in the nuclei
(Figure 1). A heterogeneous expression pattern was ob-
served regarding the percentage of positive tumor cells.
MA454 reactivity (MAGE-A1) was found in 21 of
cases (15%). In the 14 cases with moderate staining
(10.0%) this was restricted solely to the cytoplasm,
whereas in the 7 (5.0%) cases with strong staining both
the nuclei and the cytoplasm were positive.
E978 reactivity (NY-ESO-1) was also found in 21 of
cases (15%). In 15 (10.7%) cases the staining was of
moderate intensity with cytoplasmic localisation and in
6 (4.3%) samples it was strong cytoplasmatic with occa-
sional nuclear participation.
M3H67 reactivity was detected in 17 (12.9%) of cases.
Moderate staining was observed in 8 (6.1%) and strong
staining in 9 (6.8%) of cases. On the cellular level, in the
cases of moderate staining the localisation was predom-
inantly cytoplasmic and in the cases of strong staining it
was both cytoplasmic and nuclear.
MAb #26 reactivity (GAGE) was detected in 17 (12.8%)
of cases analysed. GAGE localisation was primarily cyto-
plasmic with some rare nuclear participation. ModerateTable 1 Frequency of immunohistochemical detection of
CTAs and NY-BR-1 with the corresponding mAbs in
breast cancer
n %
MAGE-A1 MA 454 21 (140) 15
mAb M3H67 17 (132) 12,9
mAb 57B 6 (133) 4,5
NY-ESO-1 E978 21 (140) 15
GAGE #26 17 (133) 12,8
MAGE-A 6C1 7 (141) 5
NY-BR-1 #5 61 (131) 46,6
n=number of cases with antigen positivity, in parenthesis total number with
successful TMA mapping for each antigen.expression was found in 9 (6.8%) and strong expression in
8 (6.0%) of cases.
57B reactivity (MAGE-A4) was found in 6 (4.5%) of
the arrays and the staining in these cases was classified
as strong. Localisation was cytoplasmic with concomi-
tant nuclear staining in approximately 20% of the nuclei
in the positive areas. In 22 (10.5%) of cases we observed
a very weak unspecific diffuse cytoplasmic staining
which was considered negative in the analyses.
Seven (5.0%) cases revealed mAb 6C1 reactivity. In 3
(2.1%) of cases the staining was moderate, predominately
cytoplasmic and to a lesser extend nuclear and in 4
(2.8%) it was strong, with both nuclear and cytoplasmic
expression.
The breast differentiation antigen NY-BR-1 was
immunohistochemically detected with the #5 Mab in the
ductal and lobular cells of all included non neoplastic
tissues as well as in 61 of 131 cases of cancer (46.6%). Its
expression was predominantly cytoplasmic in the normal
and in the tumorous tissue with nuclear participation of
varying degree. The staining intensity was classified as
moderate in 39 (29.8%) and as strong in 22 (16.8%) of
cases. Some areas with dot-like staining pattern in the
cytoplasm were also observed. No correlation was found
between expression of CTAs and NY-BR-1.
Correlations with clinico-pathological parameters
The expression data of each CTA were grouped based
on clinico-pathological characteristics (Table 2): Age
group (in comparison to median), tumor size and grade,
lymph node involvement, histological type, estrogen and
progesterone receptor and HER2/neu status were com-
pared among positive and negative samples for each
CTA. Interestingly, we observed that CTA positivity in
our cohort was restricted to grade 2 and 3 tumors and
all grade 1 tumor samples were negative for all investi-
gated CTAs. For the other examined parameters there
was no significant difference between CTA positive and
negative groups.
The expression frequency of NY-BR-1 was equally dis-
tributed among the groups with different tumor grading.
Similarly we did not find any significant differences in
the expression of NY-BR-1 related with other clinico-
pathological parameters.
Clinical outcome analysis
Factors associated with disease-free survival (DFS) and
disease specific overall survival (OS) were analysed by
Univariate Cox regression (Table 3). We observed a sta-
tistically significant negative prognostic impact for larger
tumor size (p=0.002 for both DFS and OS) and lymph
node metastases (p=0.000 for both DFS and OS). The
expression of estrogen or progesterone receptor was
accompanied by longer DFS (p=0,019), but for OS this
Figure 1 Immunohistochemical detection of cancer - testis antigens and NY-BR-1 in primary breast cancer tissue microarrays.
A: Example of moderate staining of MAGE A1 in approximately 80% of the tumor cells. The staining is restricted to the cytoplasm. B: Strong
nuclear and cytoplasmic expression of MAGE A1. C: Extensive strong nuclear and cytoplasmic M3H67 immunoreactivity. D: Strong, mainly
cytoplasmic and occasionally nuclear 57B immunoreactivity. E: Extensive strong nuclear and cytoplasmic detection of MAGE A (6C1). F: Focal
strong, mainly cytoplasmic staining of approximately 20% of tumor cells for GAGE. G: Strong extensive cytoplasmic and occasionally nuclear
staining of NY-ESO-1. H: Strong cytoplasmic NY-BR-1 staining of approximately 80% of cells with scarce nuclear detection (40x objective).
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univariate Cox regression analysis NY-BR-1 did not
seem to affect recurrence or survival.
In contrast to NY-BR-1, Kaplan-Meier survival analysis
(Figure 2) demonstrated a strong clinical impact on
survival for the immunoreactivity pattern of most of the
examined CTAs. The detected adverse effects were
statistically significant for both recurrence and disease
related death for M3H67 (p-log rank=0.004 and 0.000)
and 57B (p-log rank=0.015 and 0.036) immunoreactivity,respectively. MAGE-A1 positive patients had a shorter
OS (p-log rank =0.028), but no impact on DFS was ob-
served. Additionally we found a clear, though statistically
not significant trend for negative effects of mAb #26
(GAGE) and mAb 6C1 (MAGE-A family) expression on
DFS and OS: GAGE positive patients had a 19.9%
shorter DFS and a 14.7% shorter OS (p-log rank =0.090
and 0.238) and 6C1 positive patients a 23.19% shorter
DFS and a 16.97% shorter OS (p-log rank =0.090 and
0.453).
Table 2 Clinicopathological characteristics of breast




Tumor grade 1 7(3,50%)
2 92(45,80%)
3 102(50,70%)
Tumor size pT1 88(46,60%)
pT2 78(41,30%)
pT3/4 23(12,20%)
Lymph node status pN0 119(57,50%)
pN1/2/3 88(42,50%)
Histological type ductal 75(58,10%)
lobular 16(12,40%)
other 38(29,40%)
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strong prognosticator for overall survival
In order to identify the independent prognostic factors in
our cohort we performed a multivariate Cox regression
analysis (Table 4). Lymph node status was confirmed as aTable 3 Univariate-Cox-regression-analysis of known prognos
DFS
HR 95% CI
Age vs median 0,884 0,530–1,475
Tumor grade 1,521 0,930–2,488
Tumor stage 1,808 1,241–2,632
Lymph node status 2,971 1,730–5,104
Histological type 0,864 0,672–1,111
ER/PR status 0,526 0,307–0,901
HER2/neu status 1,064 0,826–1,369
MAGE A1 MA454 1,278 0,564–2,898
M3H67 reactivity 2,85 1,350–6,017
57B reactivity 3,406 1,15–10,03
NY-ESO-1 E978 1,272 0,563–2,877
GAGE #26 1,988 0,875–4,516
MAGE A 6C1 1,65 0,498–5,466
NY-BR-1 #5 1,522 0,816–2,839
Abbreviations: DFS Disease free survival; OS Overall survival; HR Hazard ratio; CI Conknown independent prognostic parameter with a hazard
ratio (HR) 6.37 (95% CI 2.6–17.4, p=0.0001) and 5.99
(95% CI 1.9–18.7, p=0.002) for DFS and OS respectively.
However, M3H67 reactivity exhibited the strongest prog-
nostic impact in this study, with a HR of 7.69 (95% CI
2.6–22.8, p=0.0001) for OS and the second strongest for
DFS with a HR of 4.36 (95% CI 1.2–15.6, p=0.024). Es-
trogen or progesterone receptor positivity was correlated
with decreased risk of disease recurrence (HR 0.40, 95%
CI 0.1–0.8, p=0.015) but was not included in the multi-
variate analysis for overall survival, because it did not
reach the significance threshold in univariate analysis.
Discussion
The expression of CTAs has been described in several
malignant tumors [5,6,25-27] CTAs have been identified
in melanomas, non-small cell lung and pancreatic can-
cer, serous ovarian cancer, hepatocellular carcinomas,
multiple myelomas as well as in breast cancer [17]. The
CTA expression frequency in breast cancer varies in the
literature reaching up to 88% [14]. However, the reprodu-
cibility of the studies suffers in terms of standardization
regarding tumor specimen (primary tumors or metasta-
ses), methodology (RT-PCR, Western-blot or immunohis-
tochemistry), and the evaluation of the IHC-staining.
Using a broad spectrum of diverse mAbs, we found a
total percentage for the presence of any CTA of 37.6%,
which is in accordance with most of the existing reports
[14]. However, our cohort included solely tissues from
primary tumors and in contrast to other reports we
valued all cases with weak staining as negative. One
study [4] found a positivity of 47% in primary breasttic factors CTAs and NY-BR-1 of breast-cancer patients
OS
p HR 95% CI P
0,637 0,987 0,542–1,796 0,966
0,095 1,652 0,903–3,022 0,104
0,002 1,988 1,292–3,058 0,002
0 3,348 1,714–6,537 0
0,255 0,855 0,624–1,170 0,327
0,019 0,775 0,399–1,505 0,451
0,632 0,986 0,727–1,337 0,929
0,557 2,284 0,910–5,732 0,078
0,006 4,27 1,834–9,941 0,001
0,026 3,446 1,00–11,77 0,049
0,563 0,805 0,242–2,684 0,724
0,101 1,98 0,739–5,303 0,174
0,413 1,876 0,435–8,087 0,399
0,186 1,235 0,554–2,752 0,606
fidence interval.
Figure 2 Kaplan Meier survival analysis for disease-free (DFS) and overall-survival (OS): In the presence (green line) or absence (blue
line) of immunohistochemical reactivity of M3H67 and 57B. p: log rank test.
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positive stained cells. The same authors reported a
significant higher percentage of CTA expression in
metastatic tumors (66%). These findings fit very well
into the tumorbiological context of this gene familiy and
reflect their potential role as tumor associated antigens
in tumor progression. The antibodies tested in our study
revealed the same distribution pattern, concerning
isolated cells or groups of cells, differing, however, in the
degree of expression. MAGE-A1 and NY-ESO-1 were
detected at higher frequency and we recorded neither a
significant coexpression nor a mutual exclusion of the
various CTAs, in accordance with the literature. How-
ever, we could not confirm the reported higher expres-
sion of CTAs in estrogen receptor negative cases. Ourfindings of a clear restriction of CTA expression to grade
2 and 3 cancers is in concordance with other studies
[28], however, the small number of grade 1 tumors did
not allow us to perform a reliable statistical analysis in
this case.
CTA expression was recently associated to prognosis
with an adverse impact in gastrointestinal stromal tu-
mors [25], oral squamous cell carcinomas [29], multiple
myelomas [30], and cervical cancers [31]. However,
controversial findings were also reported correlating
CTAs with a less aggressive tumor behaviour [32,33].
Our findings demonstrate a clear association for CTA
expression and prognosis. Of all the antibodies tested in
our study, M3H67 reactivity seems to exhibit the stron-
gest prognostic impact for the course of breast cancer.
Table 4 Multivariate-Cox-regression-analysis for disease-free survival and overall-survival of breast-cancer patients
DFS OS
HR 95% CI p HR 95% CI P
Tumor stage 0,807 0,435–1,496 0,496 1,393 0,658–2,948 0,386
Lymph node status 6,737 2,607–17,409 0,000 5,99 1,920–18,688 0,002
ER/PR status 0,405 0,196–0,837 0,015
M3H67 reactivity 4,355 1,218–15,572 0,024 7,693 2,597–22,786 0,000
57B reactivity 1,328 0,229–7,713 0,752 0,71 0,120–4,216 0,706
Abbreviations: DFS Disease free survival; OS Overall survival; HR Hazard ratio; CI Confidence interval.
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p53 and suppress apoptosis in MAGE-A expressing cell
lines [34]. Small interfering RNA (siRNA) suppression of
MAGE genes leads to increased p53 expression and
increased apoptosis in melanoma cell lines [34], thus the
overexpression of MAGE proteins in breast cancer could
also protect malignant cells from programmed cell
death. For MAGE-A3, specifically, a reverse correlation
is shown in pituitary tumors between tumor supressive
FGFR2 and MAGE-A3 mRNA expression [35], where
siRNA down-regulation of MAGE-A3 results in p53
promoter activation and reduced cell proliferation.
GAGE proteins seem to have a similar function, since its
transfection can render cells resistant against interferon-
gamma or death receptor Fas/CD95/APO-1 induced
apoptosis [36]. Clinically, overexpression of these pro-
teins seems, indeed, to correlate with adverse prognosis.
Due to the fact, that CTAs are relatively widely
expressed, this marker could give the additional informa-
tion for a substantial proportion of breast cancer patients.
57B reactivity had a prognostic relevance in univariate
analysis, however, it could not be validated as an inde-
pendent prognostic factor in the multivariate approach.
This limitation might be due to the relatively small num-
ber of cases available for statistical analyses. 57B
immunoreactivity has been previously associated with
poor prognosis in cholangiocarcinoma [37]. Addition-
ally, M3H67 immunoreactivity, as a marker for
MAGE-A expression, mainly MAGE-A3, was found to
be associated with poor prognosis in gastrointestinal
stromal tumors [38]. Moreover MAGE-A3 expression
detected with RT-PCR had an adverse prognostic effect in
non-small-cell lung cancers [39]. Most previous studies
also recognized an adverse correlation of MAGE A family
antigens either to the survival or indirectly to established
prognostic factors [4,40], with a unique report of
MAGE-A4 to be a favourable prognostic factor [33].
In the development of vaccines against breast cancer
two major target antigen groups have been proposed:
CTAs because of their unique expression pattern in tumor,
but not in normal tissue and the breast differentiation
antigens. Although our lack of knowledge about the
biological function of CTAs complicates their utilisation,the use of CTAs as targets for the vaccination of breast
cancer has been under debate widely the last years [41].
The exact biological function of NY-ESO-1 remains
unknown. However recent experiments indicate a possible
relevance of NY-ESO-1 expression for DNA-methylation.
[42]. The frequent expression of NY-ESO-1 in our cohort
could play a potential role in the application of additional
immunological therapies in breast cancer, since it has been
demonstrated that NY-ESO-1 can elicit strong CD8 and
CD4 T-cell response in seropositive patients [15,43,44].
Therefore it has been target of several vaccination efforts
in the past [11]. In vivo the T-cell responses against
tumor-associated antigens seem to improve the prognosis
in hepatocellular carcinoma [45]. However, suppression of
the immune response via regulatory T-cells has also been
described [46]. Several clinical trials [47] have been
performed on vaccines targeting breast cancer and two
new trials are now recruiting for the use of CTAs as tar-
gets. A recent study [16] has showed that CTA expression
is more frequent in triple negative breast cancer. This is of
particular interest, since our conventional adjuvant thera-
peutic possibilities in this subgroup of breast cancer are
limited.
An important consideration when conducting immu-
nohistochemical studies on the MAGE-A family proteins
is their high homology. Cross-reactivity of antibodies to
MAGE-A CTAs cannot be ruled out. At this point solely
mAb MA454 to MAGE-A1 can be regarded as truly
specific for a particular MAGE-A antigen. Attempts to
generate reagents to other MAGE-A family members
such as MAGE-A3, the most prevalent MAGE-A anti-
gen on a molecular level, have rendered mixed results.
This is best exemplified by mAb 57B, which was origin-
ally generated as a MAGE-A3 reagent [20]. Subsequent
analysis indicated reactivity with several MAGE-A family
members [19]. More recent data indicate reactivity of
mAb 57B to MAGE-A4 [48]. The same applies to mAb
M3H67 which was originally generated to MAGE-A3
but is now considered reactive with several members of
the MAGE-A family (unpublished data). However this
does not necessarily negatively impact the prognostic
value of immunohistochemistry, but it complicates the
identification of the best target for cancer immunotherapy.
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reacts with several MAGE-A antigens, would be more
frequent and comparable to the other anti-MAGE-A
reagents. However, in our series this was not the case. This
could be based on different affinities of the various re-
agents for similar antigens generating incongruent staining
patters in spite of overlapping specifity patterns.
NY-BR-1 can be identified at the protein level in
physiological as well as cancerous breast tissue [49]
although recently it has been also described in a vulvar
lesion [50]. The function of NY-BR-1 in vivo has not yet
been clarified. Bioinformatics analyses showing a DNA-
binding site followed by a leucine zipper motif suggest
that this molecule acts as a transcription factor. Because
of five tandem ankyrin repeats NY-BR-1 could also have
a role in protein-protein interactions [49]. Our data sug-
gest that NY-BR-1 is strongly expressed in a great pro-
portion of primary breast cancers (46.6%). This frequent
expression of NY-BR-1 has been previously described
[12]. Humoral immune response against endogenous
NY-BR-1 has been confirmed by detecting the spontan-
eous NY-BR-1 directed antibody responses in breast can-
cer patients, tested positive for NY-BR-1 by RT-PCR [51].
Additionally two HLA-A2 restricted peptide epitopes for
NY-BR-1 that were recognized by CD8+ T cells derived
from breast cancer patients have been defined [52]. Due
to the restricted expression pattern, combined with the
wide expression in tumors, NY-BR-1 seems to be an
ideal potential target for innovative immunotherapeutic
approaches of breast cancer because of the more frequent
expression in comparison to HER2/neu, the current refer-
ence target for cancer immunotherapy. This approach
exerts even more potential since we could not confirm a
recently reported correlation between NY-BR-1 and HER2/
neu expression [53].
Our analyses did not show any significant co-
expression of NY-BR-1 with the CT-antigens, neither a
mutual exclusion. Since M3H67 reactivity was associ-
ated with tumor progression while NY-BR-1 represents
a differentiation antigen it might be possible that these
tumors with a high M3H67 reactivity and simultaneous
absence of NY-BR-1 expression behave in a tumorbiological
aggressive fashion. In our cohort, we observed six such
cases with an indeed high mortality rate (50%), however
the number of cases was too small to extract any further
conclusions.
In total 60.3% of our patients were positive for either
CT-antigens or NY-BR-1 or both. Theoretically this
could facilitate polyvalent vaccines containing more than
one antigen in order to achieve in parallel targeting of a
higher percentage of tumor cells in genetically heteroge-
neous tumors, or vaccines that can be used without
prior antigen monitoring. The highly immunogenic po-
tential of CT-antigens combined with immune responseadjuvants [11] is not yet fully explored but appears
promising.
Conclusions
To our knowledge this study is the largest retrospective
analysis of the expression and prognostic role of numer-
ous CT-antigens and NY-BR-1 in breast cancer. Despite
the above limitations we believe that our results under-
line the emerging role of the above group of genes for
prognosis and therapeutical approaches in breast cancer
in the future. Especially mAb M3H67 reactivity, prob-
ably reflecting presence of several MAGE-A antigens
was proven as a strong independent prognostic factor.
The relatively small number of patients may have
concealed other important clinical correlations that
appeared only as trends. Therefore a prospective study
with a much greater number of patients and the possi-
bility of stratification according to primary and adjuvant
therapy is imperatively needed.
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